Eileen Goodwin Jeopardy Profile: Age, Job, Family, Stats

Find out all the Jeopardy! results for Eileen Goodwin, including games played, scores and competitors.

Eileen Goodwin Jeopardy Contestant Profile

Eileen Goodwin is a research scientist and immunologist based in Boston, Massachusetts, who appears on Jeopardy! as a contestant from Boston with the occupation “Research Scientist.” Her scientific background is centered on immunology, virology, antibody biology and infectious disease, particularly the way previous infections and existing antibodies influence the immune system’s response to new viral exposures.

Goodwin completed a Ph.D. in Immunology at the University of Pennsylvania’s Perelman School of Medicine, graduating in December 2024. Her doctoral research examined how prior immunity affects B-cell responses to viral antigens, with a particular focus on influenza and coronaviruses. She was co-mentored by Scott Hensley and Laurence Eisenlohr, two established researchers in viral immunology and immune-response biology.

Her dissertation was titled “The Impact of Prior Immunity on B Cell Responses to Viral Antigens.” A major part of the work examined what happens when the body already has circulating antibodies against influenza before vaccination. Using mouse models, Goodwin investigated how previously existing anti-influenza antibodies can alter the formation of new B-cell responses after vaccination.

Her research showed that circulating antibodies can suppress or redirect parts of the immune response to influenza antigens. In particular, her experiments examined antibody responses to hemagglutinin, a major influenza surface protein, and investigated how existing antibodies influence new IgM and IgG responses, plasmablast development and germinal-center B-cell activity.

This work relates to the broader immunological phenomenon historically known as original antigenic sin, now more commonly discussed as immune imprinting. The idea is that a person’s earliest or previous encounters with related viruses can shape how the immune system responds to later versions of those viruses. Goodwin’s research explored the mechanisms behind that phenomenon rather than simply documenting that it occurs.

Her doctoral work also extended to SARS-CoV-2 and other human coronaviruses. She participated in research examining whether antibodies produced against seasonal coronaviruses affected the immune response to SARS-CoV-2 infection and whether those pre-existing antibodies were associated with protection or clinical outcomes.

Goodwin was involved in several major COVID-era immunology studies. Her research contributions included investigations of antibody responses in children with COVID-19 and multisystem inflammatory syndrome in children (MIS-C), as well as broader studies comparing immune activation in pediatric and adult COVID-19 patients.

Her publication record began before graduate school. Prior to entering the University of Pennsylvania Ph.D. program, Goodwin worked at Adimab LLC in Lebanon, New Hampshire, a biotechnology company specializing in antibody discovery and engineering.

At Adimab, Goodwin contributed to research on antibody responses to serious viral infections. Her published work included studies of respiratory syncytial virus (RSV), Zika virus and ebolaviruses. These projects involved identifying, profiling and characterizing human antibodies with the potential to neutralize viruses.

One prominent line of research examined antibodies generated by infants following RSV infection. Goodwin was among the researchers studying how infants can generate potent neutralizing antibodies despite having relatively immature immune systems. This work contributed to efforts to understand how protective antibodies develop and how that knowledge could inform vaccine design.

She also contributed to research examining the antibody repertoires of adults naturally infected with RSV. That work analyzed memory B cells and identified antibodies capable of targeting key structures on the RSV fusion protein.

Goodwin participated in work on Zika virus, including research into how previous exposure to dengue virus may influence B-cell responses to Zika. The study examined both newly generated and cross-reactive memory B-cell responses, addressing an important question because dengue and Zika are closely related flaviviruses.

Another substantial part of her predoctoral research involved Ebola and related ebolaviruses. Goodwin was a contributor to studies identifying broadly neutralizing human antibodies capable of recognizing multiple ebolaviruses. Some of this research used antibodies obtained from survivors of Ebola virus infection to identify vulnerable regions on the viral surface proteins.

She contributed to research on an antibody capable of broad ebolavirus neutralization, including structural studies examining precisely how the antibody bound to conserved regions of the virus. This work was relevant to the development of antibody treatments capable of protecting against more than one ebolavirus species.

Goodwin therefore entered graduate school with substantial biotechnology research experience and an existing publication record in high-profile areas of infectious-disease immunology.

At the University of Pennsylvania, she was affiliated with the Department of Microbiology and the Immunology Graduate Group. Her work involved a mixture of experimental immunology, mouse models, human observational data, antibody assays and analysis of B-cell responses.

Her 2024 first-author work on influenza antibodies demonstrated her role not only as an experimental scientist but also in conceptualization, investigation, validation, data visualization and scientific writing. She was responsible for both drafting and revising the manuscript, reflecting substantial ownership of the project.

Her scientific career has consistently centered on one broad question: how does previous immune experience affect the way the body responds to a new viral challenge? Across influenza, RSV, coronaviruses, Zika and Ebola, Goodwin’s research has repeatedly involved antibodies and the adaptive immune system.

Her identification as a research scientist in Boston for Jeopardy! suggests that after completing her doctorate she moved into a professional research role in the Boston biotechnology or biomedical-research ecosystem. Her earlier biotechnology experience at Adimab and her Ph.D.-level expertise in viral immunology make industry or translational biomedical research a natural continuation of her career.

Contestant Image Credit: Jeopardy Official Website

Eileen Goodwin Jeopardy Results